Modulation of UBE3A-ATS expression

US9617539B2 · kind B2 · utility

Assignees

• Ionis Pharmaceuticals, Inc. · US
• Baylor College of Medicine · US

Inventors

• Frank Rigo · Carlsbad, US
• Amanda Ward · Cambridge, US
• Linyan Meng · Houston, US
• Arthur L. Beaudet · Houston, US

Key dates

• Filing date: Jun 25, 2013
• Grant date: Apr 11, 2017
• Expiry date: Jun 25, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Certain embodiments are directed to methods and compounds for inhibiting UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A). Such methods and compounds are useful for inducing expression of paternal UBE3A in cells and animals.